

PCT/US99/13744, filed June 17, 1999, designating the United States and published in English, which claims priority from United States provisional patent application 60/090,094, filed June 19, 1998.

IN THE CLAIMS

Please cancel claims 3, 5-12, 14, 23 and 24 without prejudice.

Please amend claims 17, 18, 20 and 22 as follows:*

17. (Amended) A pharmaceutical composition comprising a compound according to any one of claims 1-2, 4, or 13 or a pharmaceutically acceptable derivative thereof together with a pharmaceutically acceptable carrier therefore.

18. (Amended) The pharmaceutical composition according to claim 17, further comprising an antiviral agent other than a compound according to any one of claims 1-2, 4, or 13.

20. (Amended) A method of treating a virus infection in a human comprising administering to said human an effective antiviral treatment amount of a compound

* An "Appendix of Amendment" is enclosed at Tab A, showing the amendments to claims 17, 18, 20 and 22 and added claims 25-27. In the Appendix, the added portion is underlined and the deleted portion is bracketed.

according to any one of claims 1-2, 4, or 13 or a pharmaceutically acceptable derivative thereof.

22. (Amended) The method according to claim 20 wherein said step of administering comprises oral administration or administration by injection.

Please add claims 25-27 as follows:

25. (Added) The method according to claim 21 wherein said step of administering comprises oral administration or administration by injection.

26. (Added) A method of inhibiting aspartyl protease in a patient comprising the step of administering to said patient a compound according to any one of claims 1-2, 4, or 13 or a pharmaceutically acceptable derivative thereof.

27. (Added) A method of treating a patient diagnosed with AIDS, AIDS related complex (ARC), progressive generalized lymphadenopathy (PGL), Kaposi's sarcoma, thrombocytopenic purpura, AIDS-related neurological conditions, AIDS dementia complex, multiple sclerosis, tropical paraperesis, anti-HIV antibody-positive conditions or HIV-positive conditions, comprising the step of administering to said patient a compound according to any one of claims 1-2, 4, or 13 or a pharmaceutically acceptable